Decisional Conflicts, Health-related QoL and Satisfaction With Care in High-risk cSCC in the Head-neck Region

NCT05482880 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 78

Last updated 2026-01-06

No results posted yet for this study

Summary

Patient reported outcomes in patients with high-risk cutaneous squamous cell carcinoma in the head-neck region are an important part of the complex care for these patients. Health-related quality of life, decision conflicts in the choice of treatment and satisfaction with care have not yet been sufficiently studied in this patient group.

Conditions

  • Cutaneous Squamous Cell Carcinoma
  • Cutaneous Squamous Cell Carcinoma of the Head and Neck
  • Squamous Cell Carcinomas
  • Squamous Cell Carcinoma of Head and Neck
  • Squamous Cell Carcinoma of the Skin
  • Squamous Cell Carcinoma of the Head and Neck
  • Skin Cancer
  • High-Risk Cancer
  • Quality of Life
  • Satisfaction, Patient

Interventions

OTHER

Regular care with additionally administration of questionnaires

Patients receiving regular care. In addition, validated questionnaires are administered at two measurement points: 1. after the multidisciplinary consultation, a baseline questionnaire\*, the decision conflict scale and the EQ-5D-5L questionnaire are administered by phone. 2. 1 month after completion of the treatment program (care pathway) the EQ-5D-5L, the BaSQoL and the EORTC IN-PATSAT32 questionnaires will be administered by phone. Completing the questionnaires takes about 30 minutes each time. \*Baseline questionnaire: gender, age, marital status, education level, World Health Organization (WHO) performance status, presence of informal care, stage and treatment of cSCC, history of skin cancer, presence of current other skin cancer, and average travel time to hospital.

Sponsors & Collaborators

  • Maastricht University Medical Center

    lead OTHER

Principal Investigators

  • K Mosterd, MD, PhD · Maastricht University Medical Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-28
Primary Completion
2023-11-01
Completion
2024-12-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05482880 on ClinicalTrials.gov